Erschienen in:
01.07.2024 | Research Letter
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting
verfasst von:
Natalia Rompoti, Irene Stefanaki, Pantelis Panagakis, Charitomeni Vavouli, Maria Politou, Marina Papoutsaki, Aggeliki Befon, Fiori Koutsa, Eleni Lazou, Ioannis-Alexios Koumprentziotis, Vasiliki Chasapi, Alexander Stratigos, Electra Nicolaidou
Erschienen in:
Archives of Dermatological Research
|
Ausgabe 5/2024
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Bimekizumab is a humanized monoclonal IgG1 antibody with a unique mechanism of action, as it inhibits both IL17A and IL17F molecules. This dual inhibition is thought to be responsible for its high efficacy in treating chronic plaque psoriasis with rapid onset of action in Randomized Controlled Trials (RCTs). Concerning safety, oral candidiasis was one of the most common drug-related adverse events, commonly mild-to-moderate in severity. Although data from RCTs supporting this efficacy and safety profile of bimekizumab is numerous, results from the real-world setting concerning short- and mid-term treatment effectiveness and safety profile are limited.
Materials and Methods
An observational, retrospective, monocentric study was conducted at the Psoriasis Outpatient Unit of “A. Sygros” Hospital for Skin and Venereal Diseases, in Athens, Greece, which included 61 adult patients with moderate-to-severe skin psoriasis, who received at least one dosage of bimekizumab.
Results
At week 4, 65.7% achieved PASI75, 45.7% PASI90, and 32.4% PASI100. After 16 weeks of treatment, 92.3/76.9/66.7% of the patients achieved PASI75/90/100, respectively. Increased BMI, previous treatment with another IL-17 inhibitor, or previous exposure to another biologic did not seem to influence the possibility of achieving PASI90 and PASI100 at week 16 of bimekizumab treatment in this cohort. Six (9.8%) cases of possibly drug-related AEs were reported, from which four incidences of oral candidiasis.
Conclusion
Our results confirm that this IL17A/F inhibitor is highly effective, with a tolerability profile similar to the one expected from RCTs.